CRIS Current Research Information System

BROCCOLI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 8.374
NA - Nord America 7.903
EU - Europa 7.681
SA - Sud America 509
AF - Africa 418
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 2
Totale 24.897
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.781
SG - Singapore 2.305
VN - Vietnam 2.209
NL - Olanda 2.155
CN - Cina 2.141
IT - Italia 1.187
DE - Germania 1.040
GB - Regno Unito 945
SE - Svezia 841
HK - Hong Kong 576
BR - Brasile 372
FR - Francia 352
IN - India 323
RU - Federazione Russa 310
KR - Corea 225
IE - Irlanda 191
UA - Ucraina 157
JP - Giappone 137
FI - Finlandia 119
TG - Togo 108
ZA - Sudafrica 104
CI - Costa d'Avorio 93
EE - Estonia 72
PL - Polonia 66
CA - Canada 61
AR - Argentina 58
JO - Giordania 53
TH - Thailandia 49
BD - Bangladesh 47
ID - Indonesia 47
PH - Filippine 44
AT - Austria 38
IQ - Iraq 36
MX - Messico 36
NG - Nigeria 35
CH - Svizzera 34
ES - Italia 34
SC - Seychelles 33
BE - Belgio 28
TW - Taiwan 25
HR - Croazia 23
TR - Turchia 22
IR - Iran 20
BG - Bulgaria 17
EC - Ecuador 17
PK - Pakistan 17
SA - Arabia Saudita 17
UZ - Uzbekistan 14
VE - Venezuela 13
MY - Malesia 12
PY - Paraguay 12
CL - Cile 10
LT - Lituania 10
KE - Kenya 9
LB - Libano 9
RO - Romania 9
EG - Egitto 8
GR - Grecia 8
PE - Perù 8
AU - Australia 7
BO - Bolivia 7
PT - Portogallo 7
CR - Costa Rica 6
CZ - Repubblica Ceca 6
MA - Marocco 6
RS - Serbia 6
UY - Uruguay 6
AL - Albania 5
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
ET - Etiopia 5
OM - Oman 5
CO - Colombia 4
HU - Ungheria 4
IL - Israele 4
KZ - Kazakistan 4
PS - Palestinian Territory 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
DZ - Algeria 3
LA - Repubblica Popolare Democratica del Laos 3
MK - Macedonia 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
BN - Brunei Darussalam 2
DK - Danimarca 2
GH - Ghana 2
GY - Guiana 2
JM - Giamaica 2
KG - Kirghizistan 2
KW - Kuwait 2
LK - Sri Lanka 2
LY - Libia 2
MD - Moldavia 2
MN - Mongolia 2
PR - Porto Rico 2
QA - Qatar 2
Totale 24.873
Salva come PNG Salva come JPEG
Città #
Singapore 1.587
Eygelshoven 1.296
Ashburn 878
Southend 782
Fairfield 719
Kerkrade 666
Chandler 551
Hong Kong 537
Ho Chi Minh City 477
Hefei 451
San Jose 421
Santa Clara 402
Frankfurt am Main 399
Houston 387
Hanoi 376
Woodbridge 369
Seattle 314
Wilmington 290
Dong Ket 278
Beijing 273
Princeton 241
Ann Arbor 237
Cambridge 223
Bologna 215
Seoul 206
Dublin 191
Boardman 182
Lauterbourg 142
New York 135
Los Angeles 129
Tokyo 117
Dallas 116
Milan 110
Lomé 108
Abidjan 93
Berlin 91
Helsinki 87
Westminster 87
Nanjing 85
Padova 71
Jinan 69
Buffalo 67
Haiphong 66
Council Bluffs 60
Da Nang 60
Rome 56
Jacksonville 55
Bremen 54
Amman 53
London 53
Shenyang 50
Warsaw 48
Turin 47
Changsha 44
Bengaluru 43
Chicago 42
San Diego 42
São Paulo 42
Secaucus 41
Shanghai 41
Saint Petersburg 40
Redondo Beach 39
Falkenstein 38
Guangzhou 37
Kyiv 36
Hebei 34
Zhengzhou 34
Florence 33
Dearborn 32
Hangzhou 32
Munich 32
Nanchang 32
Phoenix 32
Hyderabad 31
Tianjin 30
Redwood City 29
The Dalles 29
Abeokuta 28
Orem 28
Des Moines 27
Jakarta 27
Jiaxing 26
Brussels 25
Lappeenranta 25
San Francisco 25
Toronto 25
Bern 24
Nuremberg 23
Amsterdam 22
Redmond 22
Düsseldorf 21
Johannesburg 21
Baghdad 20
Modena 20
Biên Hòa 17
Hải Dương 17
Olalla 17
Shenzhen 17
Brooklyn 16
Bến Tre 16
Totale 16.431
Salva come PNG Salva come JPEG
Nome #
90-yttrium-ibritumomab tiuxetan consolidation of fludarabine, mitoxantrone, rituximab in intermediate/high-risk follicular lymphoma: updated long-term results after a median follow-up of 7 years 2.843
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience 428
Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets 284
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study 257
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma. 253
High efficacy of the MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis, a 20 year experience 242
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: retrospective monocentric analysis of 14 patients 239
Design of New Personalized Therapeutic Approaches for Diffuse Large B-Cell Lymphoma through Gut Microbiome Profiling 237
Is it really possible to cure hairy cell leukemia patients only with frontline therapy? 231
(90) Y-ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) - The Zeno Study 226
Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma. 222
The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience 222
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study 216
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis. A case report and a review of literature. 216
A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report 215
Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients 206
Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. 204
Interim positron emission tomography response-adapted therapy in advanced-stage hodgkin lymphoma: Final results of the phase II part of the HD0801 study 203
Efficacy and Safety of Frontline Single‐Agent Rituximab in Extranodal Marginal Zone Lymphoma 201
Long-term responders after Brentuximab vedotin: Single-center experience on relapsed and refractory hodgkin lymphoma and anaplastic large cell lymphoma patients 201
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma 201
Economic evaluation of anti-CD19 CAR T-cell pathway for large B-cell lymphomas in the real-life setting: the experience of an Italian hub center in the first three years of activity 198
Yttrium-90 ibritumomab tiuxetan as a single agent in patients with pretreated B-cell lymphoma: evaluation of the long-term outcome. 197
The treatment of primary mediastinal large B-cell lymphoma: A two decades monocentric experience with 98 patients 196
Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. 195
PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series 191
Immunophenotype and intermediate-high international prognostic index score are prognostic factors for therapy in diffuse large B-cell lymphoma patients. 185
Collection of Hematopoietic Stem Cells after Previous Radioimmunotherapy is Feasible and Does Not Impair Engraftment after Autologous Stem Cell Transplantation in Follicular Lymphoma. 181
Brentuximab Vedotin in Transplant-Naïve Relapsed/Refractory Hodgkin Lymphoma: Experience in 30 Patients 180
The role of rituximab and positron emission tomography in the treatment of primary mediastinal large B-cell lymphoma: experience on 74 patients 179
Efficacy and safety of biosimilar epoetin alpha in patients with chronic lymphoid neoplasms and chemotherapy-induced anaemia: An observational, retrospective, monocentric analysis 179
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified. 173
A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies 173
Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma 173
Genetics and clinical phenotype of Erdheim–Chester disease: A case report of constrictive pericarditis and a systematic review of the literature 172
Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice 172
Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma 171
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: A case report and review of the literature 171
Bronchus-associated lymphoid tissue lymphomas: an update of a rare extranodal maltoma. 170
Fludarabine-Mitoxantrone-Rituximab regimen in untreated indolent non-follicular non-Hodgkin's lymphoma: experience on 143 patients 170
Angioimmunoblastic T-Cell Lymphoma 170
Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors-The MicroLinf Study 169
Bilateral orbital Erdheim-Chester disease treated with 12 weekly administrations of VNCOP-B chemotherapy: a case report and a review of literature. 169
Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma 169
Prognostic value of interim positron emission tomography in patients with peripheral T-cell lymphoma. 168
Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients 167
Hepato-gastric and spleno-mesenteric arterial trunks: anatomical variation report and review of literature 166
Cutaneous adverse-events in patients treated with Ibrutinib 166
Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. 165
Corso di malattie del sangue e degli organi emolinfopoietici 165
Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma 164
BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia 164
A Case of Bing-Neel Syndrome Treated Successfully With Ibrutinib Monotherapy Following Intensive Chemoimmunotherapy 164
The Prognostic value of tumor and microenvironment markers in classifical Hodgkin lymphoma (CHL) patients. 163
Treatment and outcomes of primary mediastinal B cell lymphoma: a three-decade monocentric experience with 151 patients 163
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 161
CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission. 161
Living Anatomy 160
Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study 159
Management of central nervous system relapse in a young patient affected by primary mediastinal large B-cell lymphoma: A case report 159
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin. 155
Extranodal marginal zone B-cell lymphoma of the lung: experience with fludarabine and mitoxantrone-containing regimens. 155
Correction: Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified (Modern Pathology, (2020), 33, 2, (179-187), 10.1038/s41379-019-0279-8) 154
Complete response of relapsed systemic and cutaneous anaplastic large cell lymphoma using brentuximab vedotin: 2 case reports. 154
Droplet digital polymerase chain reaction for the assessment of disease burden in hairy cell leukemia 154
Diagnostic accuracy of positron emission tomography/computed tomography-driven biopsy for the diagnosis of lymphoma 152
Potential survival benefit for patients receiving autologous hematopoietic stem cell transplantation after checkpoint inhibitors for relapsed/refractory Hodgkin lymphoma: A real-life experience 152
The Treatment of Burkitt Lymphoma With the Berlin-Frankfurt-Münster Protocol With Rituximab and Consolidative Autologous Transplantation 151
Hairy cell leukemia: evaluation of the long-term outcome in 121 patients. 148
Sequential therapy with alternating short courses of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) and R-FM (rituximab, fludarabine, mitoxantrone) followed by autologous stem cell transplantation results in long term remission in advanced follicular lymphoma. 148
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma. Leuk Lymphoma. 147
Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia 147
Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial 147
The prognostic value of biologic markers in classical hodgkin lymphoma (CHL) patients. 144
Hodgkin lymphoma presenting with paraneoplastic myasthenia: a case report 144
The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience 144
Single-Agent Lenalidomide Is Effective in the Treatment of a Heavily Pretreated and Refractory Angioimmunoblastic T-Cell Lymphoma Patient. 142
Outpatient experience with biosimilar filgrastim in patients with lymphoid neoplasm: Lessons from daily clinical practice 142
Hepatogastric and splenomesenteric arterial trunks: anatomical variations report 141
Short-course R-CHOP followed by (90)Y-Ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients: 7-year long-term results 141
Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome 140
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients 139
Multisystemic and Multiresistant Langerhans Cell Histiocytosis: A Case Treated With BRAF Inhibitor 139
Prolonged disease-free survival in elderly relapsed diffuse large B-cell lymphoma patients treated with lenalidomide plus rituximab 139
Genetic and phenotypic attributes of splenic marginal zone lymphoma 138
Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin. 138
Safety and Efficacy of Single-Agent Bendamustine After Failure of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin's Lymphoma: Experience With 27 Patients. 137
Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease 137
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice 133
Erythematous induration of the chest 133
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib 132
Chronic lymphocytic leukemia focus in the context of a cardiac mass in a pretreated patient: an exceptional incidental finding 132
Possible novel agents in marginal zone lymphoma 131
Ultrasound-guided core needle biopsy of nodular lesions of the spleen in hematology clinical practice 130
Clinical Features and Treatment Outcomes of Primary Cutaneous B-cell Lymphomas: A Thirty-year Experience 130
Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified 130
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. 128
Cutaneous leukocytoclastic vasculitis in B-cell chronic lymphocytic leukaemia patients 128
Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. 126
The unique biology and treatment of primary mediastinal B-cell lymphoma 125
Totale 19.892
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.433
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.433
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021736 0 0 0 0 0 0 0 0 0 0 66 670
2021/20222.125 211 60 122 258 187 110 37 159 74 153 424 330
2022/20232.566 237 371 171 333 213 204 60 191 397 85 162 142
2023/2024889 66 156 76 104 67 113 55 53 28 71 40 60
2024/20254.018 174 497 327 259 567 176 439 121 97 293 213 855
2025/202610.602 748 988 795 635 912 1.764 1.830 271 1.725 758 176 0
Totale 25.368